辛伐他汀联合非诺贝特治疗2型糖尿病并混合性高脂血症的疗效和安全性观察

目的观察辛伐他汀联用非诺贝特治疗2型糖尿病并混合性高脂血症的疗效及安全性。方法共入选80例2型糖尿病并混合性高脂血症患者,随机分为2组,其中联合用药组给予辛伐他汀10mg/d,非诺贝特200mg/d;辛伐他汀组单用辛伐他汀20mg/d,疗程均为6个月,观察治疗前后主要血脂参数的变化率、达标率以及总有效率和不良反应。结果联合用药组治疗6个月后血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)分别下降31%、38%和55%,而血清高密度脂蛋白胆固醇(HDL-C)升高22%,明显优于辛伐他汀组(变化率分别为21%、28%、10%和5%),2组比较差异有非常显著意义(P<0.01)。联合用药组不良反应发生率和辛伐他汀组相比差异无显著意义(P>0.05)。结论联合应用辛伐他汀和非诺贝特可以更全面地改善2型糖尿病并混合性高脂血症患者的血脂异常,较单用辛伐他汀更有效,且具有良好的安全性和耐受性。

Efficacy and safety of combined therapy with simvastatin and fenofibrate for type 2 diabetes patients with mixed hyperlipidemia

Objective To investigate the efficacy and safety of combined therapy with simvastatin and fenofibrate for type 2 diabetes patients with combined hyperlipidemia.Methods Eighty type 2 diabetes patients with mixed hyperlipidemia were randomly divided into two groups.The patients in group A were administered simvastatin (10 mg/d) and fenofibrate (200 mg/d)during six months,the patients in group B took orally simvastatin (20 mg/d) for six months.The blood lipid were determined before and after treatment,and side effects were observated during the period.Results Comparing with those before treatment,the decreasing degree of TC,LDL and TG were separately 31%,38% and 55%,the level of HDL increased 22% in group A,They were 21%,28%,10% and 5% in group B,there was signifcant difference between the two groups (P<0.01).There was no difference about the rate of side effects during the period between the two groups (P>0.05).Conclusion Combined therapy with simvastatin and fenofibrate for type 2 diabetes patients with mixed hyperlipidemia could be safe and more effective.